Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing based on Patient Clinical Outcomes
Study identifier:D961HL00020
ClinicalTrials.gov identifier:NCT02477475
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to investigate treatment response to NEXIUM in patients with reflux esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing based on Patient Clinical Outcomes
Medical condition
reflux esophagitis
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
1595
Study type
Observational
Age
N/A
Date
Study Start Date: 07 Jul 2015
Primary Completion Date: 20 Feb 2017
Study Completion Date: 20 Feb 2017
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2017 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| NEXIUM Oral dose 20mg/day | - |
Contacts
Investigators
Principal Investigator
Shigeru Yoshida
AstraZeneca K.K.
